Participating Companies

Alladapt Immunotherapeutics, Inc.
Developing a potentially best-in-class oral immunotherapy that addresses a broad range of food allergies. ADP101, which is currently in a Ph 1/2 clinical trial, is designed to desensitize patients allergic to one or to multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions. The Company was co-founded by Dr. Kari Nadeau, a renowned food allergist, and former 23andMe exec, Ashley Dombkowski who serves as Alladapt’s CEO. To date, the company has raised $63 million. [more information]

Amphista Therapeutics
Identified novel degrading mechanisms independent of typical E3 ligases • Building on strengths of TPD while directly addressing limitations • Demonstrated superiority over other TPD approaches across three separate areas: increased scope, improved druglike properties and reduced resistance potential • Initial focus in Oncology with scope to expand into further therapy areas, including CNS diseases Amphista Therapeutics successfully closed an oversubscribed $53M Series B round in March 2021, building on an initial $7.5M Series A funding raised in April 2020. [more information]

Arbor Biotechnologies
An early-stage life sciences company pioneering the next-generation of genetic medicines. With the most extensive library of CRISPR nucleases in the industry, a deep bench of world-class founders (including gene editing pioneer Feng Zhang) and scientific advisors, and a leadership team with a proven track record of developing novel platforms and therapeutics, Arbor is well-positioned to develop curative genetic medicines for all patients with genetic diseases. [more information]

Atomwise
Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. [more information]

CAMP4
Developer of a platform to discover effective treatment approaches for every disease. The company's gene circuitry platform solves the circuitry code, unique to each human gene, facilitating the rapid discovery of new treatments. Its 4D maps identify de-risked druggable targets, produce actionable insights and improve therapeutic predictability. [more information]

Carisma Therapeutics Inc.
- CARISMA Therapeutics Inc. is a clinical stage biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. CARISMA Therapeutics is headquartered in Philadelphia, PA. [more information]

Catamaran Bio
The Company is using its TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance its pipeline of CAR-NK cell therapy programs. [more information]

Celsius Therapeutics
Provider of a platform intended to research on single-cell RNA sequencing and genomic analysis to develop life-changing medicines. The company's platform applies systematic approach to single-cell sequencing, combining massive datasets and algorithms in order to discover precision therapies, enabling doctors to impact on the lives of patients with autoimmune diseases and cancer. [more information]

Chameleon Biosciences
The company's technologies include effector vectors and exo-AAV which are not constrained by the same immune system limitations that prevent more widespread use of current AAV gene therapies, enabling patients to treat rare diseases with genetic medicines administered as many times as needed. [more information]

Clerio Vision, Inc.
Novel ophthalmic technology to treat refractive error addressing multi-billion markets in contact lenses (presbyopia, astigmatism, myopia, myopia progression) and corneal vision correction (non surgical flapless laser solution). Omnifocal contact lens presbyopia 510k submission and myopia progression clinical data in 2H2022. Based on Nobel Prize winning femto-second laser technology developed by Bausch & Lomb and the University of Rochester. [more information]

Cytoimmune Therapeutics
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. [more information]

DTx Pharma
Developer of an RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company's technology enables efficient delivery of nucleic acid drugs to tissues throughout the body, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses that work in many cell types including neurons, endothelial and T cells. [more information]

Enterome
Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health. Enterome’s success is based on its unique ability to identify small proteins and peptides from gut bacteria that can deliver a therapeutic benefit in humans. [more information]

Evox Therapeutics
Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space. [more information]

Hangzhou Chance Pharmaceuticals
Chance focuses on inhalation products with proprietary technologies. [more information]

HotSpot Therapeutics
The company helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases. Its platform leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery. [more information]

Impact Therapeutics Inc
IMPACT and Junshi Biosciences established a 50:50 joint venture that focuses on the development and commercialization of Senaparib in China. The JV is currently conducting a Phase II pivotal study and a Phase III study of Senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. [more information]

Imvax
Imvax™ is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. [more information]

Invetx
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians. Invetx is a private company headquartered in Boston, Massachusetts. [more information]

Lassen Therapeutics
IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be more effective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. [more information]

LiPac Oncology
LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development. [more information]

MiNA Therapeutics
Leader in a new class of RNA medicines - RNA activation (RNAa) therapeutics platform, initially focusing on immuno-oncology and rare disease indications with 10 clinical assets expected by 2025 and first FDA approval in 2024. Key programs include MTL-CEPBA (clinical POC in 2L HCC), MTL-STING, monogeneic rare disease programs. $1.5B+ pharma partnerships. [more information]

Minerva Biotechnologies
immunotherapies for cancer and cellular therapies in regenerative medicine. First-in-human trial of huMNC2-CAR44, a CAR T therapy targeting MUC1* in metastatic breast cancers in patients with MUC1* reactive tumors. IND for 1XX version of this CAR T, which greatly increases persistence and recognition of low antigen density cells will be filed in 2021. [more information]

MISSION Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. [more information]

NKGen Biotech
is a clinical-stage biotechnology company focused on the development and commercialization of unique autologous, allogeneic, and CAR-NK Natural Killer (NK) Cell therapies. [more information]

NodThera Limited
Operator of a clinical-stage biotechnology company intended to develop medicines to treat diseases driven by chronic inflammation. The company is focused on developing a new class of potent and selective NLRP3 inflammasome inhibitors, providing medical practitioners with tools to help patients with many chronic diseases. [more information]

NorthSea Therapeutics
Focused on developing SEFAs for the treatment of NASH and other metabolic disorders. Lead product, icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA 1024 is in phase 1 to be developed for dyslipidemia and SEFA 6179, [more information]

OncoResponse
In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. [more information]

Orum
Strong R&D team with industry veterans in mAb/ADC discovery and physics based modeling provides Orum with an unmatched R&D engine to discover and develop multiple platforms with pipeline products with precision and speed. [more information]

Plexium
Plexium’s targeted protein degradation platform, DELPhe®, enables the discovery of novel small molecules with cell-based activity that redirect E3 ligases to pathogenic proteins of interest or induce degradation of pathogenic proteins by directly binding to them. [more information]

Prilenia
Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success.
Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS.
The company has recently raised $68.5M in a Series A financing round to launch [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

Revitope Oncology
The leading next generation conditionally activated T cell engager company leveraging its TwoGATE™ platform to address areas of unmet need for safer and more effective cancer immunotherapies. Revitope’sTwoGATE™ drugs target a pair of antigens co-expressed on the surface of cancer cells to achieve an unparalleled degree of tumor selectivity and avoid toxicity on healthy cells and tissues.” [more information]

Shoreline Biosciences
Shoreline Biosciences is developing clinically effective allogeneic, off-the-shelf, targeted, and standardized immunotherapies using intelligently engineered induced Pluripotent Stem Cell (iPSC)-derived NK cells and macrophages for serious diseases. [more information]

ShouTi Inc.
ShouTi’s vision is to improve world health by better treating chronic diseases such as cardiovascular disease and diabetes which are rapidly increasing and represent over 60% of the global disease burden. ShouTi’s first drug candidate entered human clinical trials in May 2021 and a second molecule is expected to enter the clinic in early 2022. [more information]

Solebury Trout
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. [more information]

SparingVision
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. [more information]

SphingoTec GmbH
SphingoTec’s first-in-class tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for acute care. [more information]

Systems Oncology
Ddeveloping a new class of multimodal RNA therapeutics that simultaneously silence the right combination of disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our ArromerTM platform is used to digitally engineer and rapidly produce self-delivering therapeutics which are directed to specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of drug products in oncology, yet our multimodal RNA therapeutics platform can be [more information]

Tarveda Therapeutics
is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors. PEN-221 is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors. [more information]

Totus Medicines
[more information]

Treos Bio Limited
Develops precision peptide cancer immunotherapies using patient HLA target recognition genetics based on proprietary computational data science. Treos’ lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a biomarker-based Phase 1b clinical trial. Treos has raised $42 million to date. [more information]

XyloCor Therapeutics
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. [more information]